MSMS Foundation and Molina Healthcare of Michigan Announce Provider Shortage Area Scholarship Recipients
The MSMS Foundation and Molina Healthcare of Michigan have announced the recipients of their Provider Shortage Area Scholarships, an initiative designed to address critical healthcare workforce shortages in Michigan's underserved communities. Five Michigan students—Whitney Bowyer, Selena Croskey, Jeren Ghoujeghi, Aden Smith, and Tiffany Tessmer—were selected for their academic excellence, financial need, and commitment to community-based care. These recipients plan to serve various medical fields in Detroit and rural northern Michigan, focusing on areas with significant healthcare access gaps.
TD Cowen backs UnitedHealth & Humana with buy upgrades, shares rise
TD Cowen has upgraded UnitedHealth (UNH) and Humana (HUM) from 'Hold' to 'Buy', leading to a rise in their premarket shares. The upgrades are based on an improved outlook for both health insurers and potential for further upside.
Humana and Sprouts Farmers Market have been highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research has identified Humana (HUM) as its Bull of the Day due to its strong performance, recovery in Medicare Advantage Star Ratings, and positive earnings outlook. Conversely, Sprouts Farmers Market (SFM) was named the Bear of the Day, facing challenges with declining traffic, price investment impacting margins, and a negative earnings forecast. The article also touches on the cybersecurity sector, noting the rising importance and opportunities for companies like Palo Alto Networks (PANW), CrowdStrike Holdings (CRWD), and Fortinet (FTNT) amidst increasing AI-powered cyber threats.
Bull of the Day: Humana (HUM)
Humana (HUM) has transformed from a struggling managed care company to a top performer within a year, driven by a successful turnaround in its Medicare Advantage Star Ratings. The company exceeded its quality goals and posted strong third-quarter results, prompting analysts to raise earnings estimates for both the current and next year. Humana's stock has gained 48% year-to-date and is seen as a compelling investment due to strong fundamentals and a powerful technical uptrend.
Health Insurers Sink on Sanders’ Medicare for All Plan
US health insurance stocks experienced a significant downturn following announcements of new federal audits for Medicare and Senator Bernie Sanders' proposals for expanded Medicare eligibility. UnitedHealth Group Inc., the largest insurer, saw its shares drop by as much as 21%, wiping out almost all its year-to-date gains due to these developments.
93% of private Medicare plans offered by eHealth cover a drug for obesity in 2027, if patients qualify; 5% did in 2026.
A new eHealth report reveals that 75% of Medicare beneficiaries used AI tools to review their 2027 plan options. Notably, 93% of eHealth's 2027 Medicare Advantage plans now cover at least one GLP-1 drug for obesity, a significant increase from 5% in 2026. Despite technological assistance, cost remains a concern, with 63% of beneficiaries surprised by high monthly premiums and an 8% increase in average out-of-pocket maximums for selected plans.
Medicare Annual Enrollment Halftime Report: 75% of enrollees have used AI tools to review 2027 Medicare plans
A new eHealth report reveals that 75% of Medicare beneficiaries who reviewed their 2027 plan options utilized AI tools, although licensed insurance agents remain the primary choice for plan selection. The report also highlights a significant increase in Medicare Advantage plans offered by eHealth covering GLP-1 drugs for obesity and growing optimism about healthcare affordability post-mid-term elections, despite concerns about rising premiums and out-of-pocket costs.
There May Be Some Bright Spots In Humana's (NYSE:HUM) Earnings
Humana's recent earnings report, despite appearing soft, has underlying positive factors. The company's strong accrual ratio of -0.23 indicates that its free cash flow significantly exceeds its reported profit, with FCF at US$3.1b compared to US$1.25b in profit. Additionally, unusual items that reduced profit by US$432m are likely one-off, suggesting future profitability could be higher.
Humana Inc. Stock 12‑Month Price Target Raised to $515.13, Implies 34% Upside
Humana Inc.'s average 12-month price target has been increased to $515.13 by 23 analysts, up from $510.57. This new target suggests a potential upside of approximately 34% based on the Nov. 18 closing price. The consensus rating for Humana Inc. remains "Buy" among 29 analysts, with 18 recommending "Buy" and 11 recommending "Hold."
Universal Electronics director Satjiv Chahil sells $703,700 in shares
Satjiv S. Chahil, a director at Universal Electronics Inc. (UEIC), sold 125,000 shares of the company's common stock for $703,700 on November 17, 2026. This transaction occurred as UEIC stock has seen a 108% surge over the past year, with InvestingPro analysis suggesting it remains undervalued. Following the sale, Mr. Chahil indirectly holds 75,704 shares through a trust.
Which Monthly Check Swings the Most? QYLD, PGX and MUB Side by Side
This article compares the monthly distribution volatility of three income ETFs: QYLD, PGX, and MUB, over a two-year period. QYLD showed the highest variation at 18.5% due to its option premium-based payouts, while PGX had moderate swings at 7% from preferred dividends, and MUB was the steadiest at 2.1% from municipal bonds. The author suggests each ETF suits different investor needs based on their tolerance for payment variability and tax considerations.
DaVita Inc. (DVA) Stock forecasts
Argus has lowered its target price for DaVita Inc. (DVA) to $164.00, citing the company's position as the largest provider of dialysis services in the U.S. with about 35% market share. The current stock price for DVA is $156.34. The report was published on November 18, 2026.
Humana (HUM) Stock Trending After Hours as CMS Proposes $90B Medicare Anti-Fraud Rule
Humana (HUM) shares were trending after hours, slipping 0.46% following a 12.98% decline in the regular session. This activity comes after the Centers for Medicare & Medicaid Services (CMS) proposed a new Comprehensive Regulations to Uncover Suspicious Healthcare rule. This rule aims to save nearly $90 billion over 10 years by targeting fraud and abuse across various healthcare programs, particularly through stronger Medicare Advantage Risk Adjustment Data Validation audits.
Humana (HUM) Stock Trending After Hours as CMS Proposes $90B Medicare Anti-Fraud Rule
Humana (HUM) shares were trending after hours, slipping 0.46% following the Centers for Medicare & Medicaid Services (CMS) proposal of a new anti-fraud rule. This rule, which targets fraud, waste, and abuse across several healthcare programs, could save taxpayers nearly $90 billion over 10 years. For insurers like Humana, the primary change involves stricter Medicare Advantage Risk Adjustment Data Validation audits to recover improper payments.
Humana Drops 6.4% Amid Sector-Wide Selling
Humana Inc. shares fell 6.4% to $415.14, caught in a broad sector-wide selloff affecting managed care and health insurance stocks. The decline was not company-specific, as peers like UnitedHealth Group and Elevance Health also saw significant drops, suggesting broader market concerns rather than individual company issues. Despite the sharp decline, analyst sentiment remains constructive with no recent price target cuts, indicating that Wall Street's view of Humana's fundamentals has not materially shifted.
Cytokinetics chief legal officer sells $794,877 in shares
Jeffrey Hessekiel, Cytokinetics' Chief Legal & Admin Officer, sold 15,106 shares of the company's common stock for $794,877 to cover tax withholding obligations. This "sell to cover" transaction was mandated and not discretionary, occurring while the stock trades near its 52-week low. Despite recent strong Q3 2026 financial results, analysts and InvestingPro still consider the stock undervalued with optimistic price targets.
Abrams Capital Management sells $182.85M in Loar Holdings stock
Abrams Capital Management, a 10% owner and director of Loar Holdings Inc. (LOAR), recently sold approximately $182.85 million worth of common stock over two days in mid-November. Following these transactions, the firm still beneficially owns over 29 million shares, held indirectly through various affiliated funds. Concurrently, Loar Holdings reported strong third-quarter revenue, exceeding expectations and leading to an upward revision of its full-year outlook, with Jefferies raising its price target on the stock.
Richard Schwartz, Rush Street Interactive CEO, sells $1.79M in stock
Richard Schwartz, CEO of Rush Street Interactive (NASDAQ:RSI), sold 152,842 shares of Class A Common Stock for approximately $1.79 million on November 16, 2026. This sale occurred while the stock was trading near its 52-week low after a 58% decline over six months. The transactions were part of a pre-arranged 10b5-1 trading plan and involved shares held directly by Schwartz and indirectly through trusts.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana, Centene and Molina
The U.S. health insurance industry, particularly Health Maintenance Organizations (HMOs), is experiencing growth supported by diversified health plans, an aging population, and technological advancements like telehealth and AI. Despite regulatory challenges such as Medicaid eligibility checks and expiring ACA subsidies, strategic acquisitions and Medicare Advantage rate increases are bolstering the sector. Zacks Investment Research highlights five key players—UnitedHealth Group, Cigna, Humana, Centene, and Molina Healthcare—as well-positioned to capitalize on these dynamics.
Healthcare stocks (UnitedHealth, Humana, CVS, Cigna) fall on new Medicare rules
Shares of major healthcare insurers like UnitedHealth, Humana, CVS Health, and Cigna Group dropped following new Medicare rules proposed by the Centers for Medicare & Medicaid Services (CMS). These stricter oversight measures, particularly expanded Medicare Advantage audits and retrospective payment recoveries, raised concerns about future profitability, with CMS estimating potential federal budget savings of nearly $90 billion. While investment banks maintain generally positive price targets, the selloff highlights investor apprehension regarding regulatory challenges and their impact on earnings.
Humana Drops 8.5% Intraday: What the Selloff Looks Like
Humana (HUM) experienced an 8.5% intraday drop, falling from its $441.37 open to stabilize in the low $400s, an unusually sharp move for a large managed-care insurer. Competitor Clover Health (CLOV) also fell by 7.2%, suggesting an industry-wide event rather than company-specific news. Investors are closely watching whether the $401 intraday low will hold as a support level.
Houston Food Bank receives $100,000 grant as Humana Foundation announces nearly $14 million in funding
The Houston Food Bank has received a $100,000 grant from the Humana Foundation to support its senior food program, helping older adults overcome financial and transportation barriers to nutritious meals. This grant is part of a larger nearly $14 million nationwide investment by the Humana Foundation aimed at addressing food insecurity, improving emotional health, and supporting community programs across the country. The funding emphasizes the foundation's commitment to improving health outcomes by tackling challenges beyond traditional medical care, especially for underserved older adults.
Humana Drops 6.4% Amid Sector-Wide Selling
Humana Inc. shares dropped 6.4% on Wednesday, reflecting a broad sector-wide selloff that impacted managed care and health insurance stocks like UnitedHealth Group, Elevance Health, Centene, Molina Healthcare, and Clover Health. The decline was not company-specific, suggesting broader concerns about the healthcare coverage sector rather than Humana's fundamentals. Despite the drop, analyst sentiment remains constructive, with no recent price target cuts.
Molina Healthcare Drops 5.9% Amid Sector-Wide Selling
Molina Healthcare's stock fell 5.9% on Wednesday, closing at $208.22, as part of a broad selloff impacting managed care companies. Major competitors like UnitedHealth Group, Humana, Centene, Elevance Health, and Clover Health also experienced significant declines, indicating a sector-wide retreat rather than company-specific issues for Molina. The synchronized drop suggests a shift in investor sentiment regarding the managed care industry's outlook or risk profile.
Should You Buy, Sell or Hold Ethereum Before Year-End?
Ethereum is currently trading at $1,773, significantly down from its August 2025 high, leading investors to question whether to buy, sell, or hold before year-end. While BitMine Immersion Technologies is aggressively increasing its ETH holdings and staking most of it, sustained outflows from Ethereum funds and a postponed upgrade are bearish indicators. For most investors, holding appears to be the most prudent option to avoid locking in losses, though tax-loss harvesting could make selling attractive for some.
Few payers are ready for looming electronic prior authorization deadline
A new survey by the Workgroup for Electronic Data Interchange (WEDI) reveals that only 1 in 10 payers are fully prepared to implement the electronic prior authorization requirements mandated by a 2024 regulation, despite a January 1 deadline. Payers are facing significant challenges with system connectivity, workflow adaptation, and higher-than-anticipated costs for compliance with the API requirements. While most payers are at least halfway there, providers are also largely unprepared, highlighting the complexity and cost of the new interoperability rules.
UnitedHealth, Humana and Elevance fall sharply after Medicare audit proposal
UnitedHealth, Humana, and Elevance Health experienced significant stock declines following a CMS proposal to extend Medicare Advantage audit recoveries back to 2018. The proposal, which could amount to roughly $9 billion per payment year, led to a combined paper loss of about $43 billion for the three companies by early afternoon on November 18, 2026. Analysts expect potential legal challenges to the rule, with Oppenheimer suggesting recoveries may be concentrated later and priced into future bids.
UnitedHealth and Humana fall after CMS proposes a $90 billion anti-fraud rule
Shares of UnitedHealth Group, Humana, CVS Health, and Cigna fell after the Centers for Medicare & Medicaid Services (CMS) proposed a new Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) rule. This rule aims to recover an estimated $90 billion over 10 years through tougher audits of Medicare Advantage insurers, extrapolating audit findings and requiring reporting of suspected fraud. The proposal, scheduled for publication on November 19, 2026, is open for comments until January 19, 2027, and follows a previous court setback for similar provisions.
Quanterix Corporation FY26 Results: Sales guidance affirmed at $142M-$146M
Quanterix Corporation has reaffirmed its full-year fiscal 2026 sales guidance, projecting revenue between $142 million and $146 million, which aligns closely with the analyst consensus of $143.357 million. This steady forecast indicates the company's confidence in its current operational trends and a cautious revenue trajectory for the upcoming fiscal year. The guidance suggests stable expectations, with the analyst estimate falling within the lower half of the company's projected range.
UnitedHealth, Humana Tumble as CMS Unveils $90 Billion Anti-Fraud Crackdown
Managed care shares, including UnitedHealth and Humana, dropped sharply after the Centers for Medicare & Medicaid Services (CMS) proposed the CRUSH rule, an anti-fraud initiative estimated to save nearly $90 billion over 10 years. The proposal aims to expand audits, tighten provider screening, and allow CMS to recover improper payments across various health programs. Oppenheimer analysts, however, cautioned about potential legal challenges and suggested that insurers might pass added costs into future bids.
Humana drops 9% on proposed Medicare fraud crackdown (HUM:NYSE)
Humana shares fell over 9% after news broke of a proposed federal "CRUSH rule" targeting fraud and waste in Medicare, Medicaid, and the Health Insurance Marketplace. The stock traded at $404.69, down $38.65, in midday trading on Thursday. This decline reflects investor concern over potential impacts of stricter regulations on the healthcare insurer's operations.
Alignment Healthcare falls 9% amid weakness in Medicare Advantage stocks (ALHC:NASDAQ)
Alignment Healthcare (ALHC) shares dropped almost 9% to $6.96 on Wednesday, coinciding with a broader weakness in Medicare Advantage stocks. This decline also impacted peers like Humana (HUM), which was down nearly 8%. The article indicates a general downturn in the Medicare Advantage sector.
Josh Brown Says Netflix Trades at 16 Times Next Year's Earnings After a 50% Drop. Is It a Buy?
Josh Brown, CEO of Ritholtz Wealth Management, notes that Netflix (NFLX) is trading at 16 times next year's earnings estimates after a 50% decline from its high. Despite a strong Q3 performance with expanded operating margins and a record share buyback, factors like slower ad rollouts, cooling U.S. growth, and falling Q4 estimates contribute to its discounted valuation. The stock's future re-rating depends on the timely execution of ad strategies and the production of new original content hits.
Plug Power Rallies 6% After Fuel Cell Selloff; FuelCell Dips, Bloom Energy Holds Steady
Plug Power (NASDAQ:PLUG) stock rallied 6% to $1.11 after a recent fuel cell selloff, despite still being down 43% year-to-date. The company's Q3 2026 revenue beat expectations, and gross margin improved significantly, though profit was flattered by non-cash gains. Meanwhile, FuelCell Energy (NASDAQ:FCEL) saw a slight dip but remains up 12% YTD, and Bloom Energy (NYSE:BE) held steady, up 100% YTD, benefiting from its larger scale and profitability.
Wafd stock hits 52-week low at 28.1 USD
WaFd Inc.'s stock has fallen to a 52-week low of $28.10, reflecting decreased investor confidence and a 9.76% decline over the past year. Despite this, InvestingPro analysis suggests the stock is undervalued with a P/E ratio of 8.82 and a PEG ratio of 0.4, indicating potential for near-term earnings growth. The company also maintains a consistent dividend payment history for 44 consecutive years, offering a 3.82% yield.
Why Microsoft Could Surprise and Hit $4 Trillion Before NVIDIA Does
Microsoft and NVIDIA are both nearing a $4 trillion market capitalization, with their values currently around $3.75 trillion. The article suggests Microsoft might reach this milestone first due to its robust, diversified business operations and a significant $677 billion backlog that is not dependent on immediate chip orders. While NVIDIA boasts faster growth and innovative hardware like Vera Rubin systems, its higher stock volatility and reliance on a few major customers introduce more risk, potentially giving Microsoft a quieter, more stable path to the $4 trillion valuation.
Florida Seniors and Primary Care Providers Agree that Prevention, Affordable Care and Comprehensive Coverage are Keys to Healthy Aging
Humana commissioned two Morning Consult surveys of Florida seniors and primary care providers, highlighting affordability, prevention, supplemental benefits, and coordinated care as top priorities for healthy aging. The surveys suggest strong retention for Medicare Advantage plans, with 97% of current enrollees planning to stay. However, both providers and seniors identified out-of-pocket and prescription drug costs as significant barriers.
Florida Seniors and Primary Care Providers Agree that Prevention...
Humana-commissioned surveys of Florida seniors and primary care providers indicate that affordability, prevention, supplemental benefits, and coordinated care are key priorities for healthy aging. The surveys also show high retention rates for Medicare Advantage members and highlight out-of-pocket and prescription drug costs as significant barriers. This release serves as a promotional piece for Humana's Medicare Advantage plans, framing survey results to support its product.
Zacks Industry Outlook Highlights UnitedHealth, The Cigna, Humana, Centene and Molina
The U.S. health insurance (HMO) industry faces both opportunities and challenges, with diversified health plans and an aging population supporting membership and demand for Medicare. Regulatory changes like Medicaid eligibility checks and expired ACA subsidies threaten enrollment, while technological advancements like AI and telehealth improve efficiency but carry implementation costs. Industry leaders like UnitedHealth Group, Cigna, Humana, Centene, and Molina Healthcare are well-positioned to leverage these dynamics, supported by strategic acquisitions and an optimistic Zacks Industry Rank.
TNL Mediagene regains Nasdaq compliance after asset sale
TNL Mediagene (NASDAQ:TNMG) has regained compliance with Nasdaq's minimum stockholders' equity requirement following the sale of its Japanese operating subsidiaries. The company will be subject to a one-year Mandatory Panel Monitor, during which any new non-compliance with the equity rule will result in a delisting determination without further opportunity for a compliance plan. TNL Mediagene is a Taipei-headquartered technology and digital media company.
PACE Organization InnovAge Agrees to Pay $36M to Resolve False Claims Act Allegations
InnovAge Holding Corporation has agreed to pay $36 million to settle allegations that it violated the False Claims Act and state laws. The company is accused of failing to provide comprehensive medical services and timely specialist referrals to its elderly patients enrolled in the PACE program. This settlement highlights the government's commitment to holding PACE organizations accountable for the care of vulnerable seniors.
UnitedHealth Shares Slide 5.4% Amid Scrutiny Over Conglomerate Structure and Medicare Oversight
UnitedHealth Group Inc. shares dropped 5.42% following renewed calls from Senator Elizabeth Warren to break up major healthcare conglomerates with the proposed Break Up Big Medicine Act. This legislative push, coupled with the Centers for Medicare & Medicaid Services proposing the CRUSH rule to tighten Medicare Advantage regulations, intensified scrutiny on UnitedHealth's integrated business model. Despite strong third-quarter earnings, the company's stock underperformed the market.
UnitedHealth (UNH) vs. Humana (HUM): Buy the Dip?
Shares of UnitedHealth (UNH) and Humana (HUM) recently pulled back due to new regulatory scrutiny concerning Medicare Advantage, despite both companies reporting strong Q3 earnings and raising their full-year guidance. Analysts have responded with upward earnings estimate revisions for both, suggesting the dip might be a buying opportunity for long-term investors. While Humana has significantly outperformed UnitedHealth in 2026, UnitedHealth offers a more attractive valuation and a higher dividend yield.
Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments
The Centers for Medicare & Medicaid Services (CMS) has proposed significant program integrity reforms aimed at combating fraud, waste, and abuse across federal healthcare programs, potentially saving nearly $90 billion over the next decade. The "Comprehensive Regulations to Uncover Suspicious Healthcare" rule strengthens Medicare Advantage audits, mandates reporting of suspected fraud, and protects seniors from unwanted solicitations. Additionally, it tightens oversight for Medicaid and CHIP and prevents unauthorized enrollments in the Health Insurance Marketplace.
UnitedHealth (UNH) vs. Humana (HUM): Buy the Dip?
Shares of UnitedHealth and Humana experienced a pullback due to renewed regulatory scrutiny over proposed Medicare Advantage regulations. Despite this, both companies recently exceeded Q3 earnings expectations and raised their full-year guidance, leading to positive earnings estimate revisions from analysts. This selloff could present a buying opportunity for long-term investors, with UnitedHealth offering a more attractive valuation and dividend, while Humana boasts stronger recent stock performance and a Zacks Rank #1.
CVS Health Stocks Fall 3.12% as Aetna Faces Tougher Medicare Advantage Audit Rules
CVS Health shares dropped 3.12% after the Department of Health and Human Services proposed new rules to toughen audits of Medicare Advantage plans, including CVS's Aetna unit. The proposed rule would allow CMS to extrapolate risk adjustment audit results across entire contracts, impacting managed care companies. Despite CVS having a diversified business with pharmacy and benefits, investors are awaiting management's exposure estimates regarding the potential impact of these new regulations.
Invesco Equal Weight 0-30 Year Treasury ETF faces risks amid inflation and strong labor market.
The Invesco Equal Weight 0-30 Year Treasury ETF (GOVI) is facing significant pressure due to persistent inflation and duration risk, despite its potential as a safe haven if AI negatively impacts employment. With a strong current labor market, this benefit is diminished. The ETF, established in 2007 with $1 billion in assets, is considered unsuitable for the prevailing macroeconomic conditions, urging investor caution.
Humana to mandate office work for select Louisville staff
Humana is implementing a new policy requiring select Louisville staff to work from the office, beginning in early 2027. This decision is part of the insurer's strategy to establish talent hubs in nine cities, focusing on roles that benefit from in-person collaboration.
If You Invested $1000 In Humana Stock 20 Years Ago, You Would Have This Much Today
This article examines the hypothetical growth of a $1,000 investment in Humana (NYSE: HUM) stock over the past 20 years. Humana has outperformed the market with an average annual return of 11.27%. The initial $1,000 investment would now be worth $8,456.22, highlighting the power of compounded returns over time.
Humana Inc. stock outperforms competitors despite losses on the day
Humana Inc. (HUM) shares fell 3.88% to $443.34 on Tuesday, breaking a two-day winning streak, despite an overall grim trading session where the S&P 500 Index and Dow Jones Industrial Average also experienced significant declines. The company's stock performance is highlighted in the context of broader market losses.